Trial · NCT03453619
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part A: Change From Baseline in Proteinuria at Week 48 | Part A: IgAN Subjects | -0.1364 | 95% Confidence Interval -1.0641 to 0.7913 | ratio | |
| Part A: Change From Baseline in Proteinuria at Week 48 | Part A: LN Subjects | 0.3560 | 95% Confidence Interval NA to NA | ratio | |
| Part A: Change From Baseline in Proteinuria at Week 48 | Part A: PMN Subjects | 0.3430 | 95% Confidence Interval NA to NA | ratio | |
| Part A: Change From Baseline in Proteinuria at Week 48 | Part A: C3G Subjects | -2.0347 | 95% Confidence Interval -3.9033 to -0.1662 | ratio | |
| Parts A and B: Change From Baseline in Serum Complement 3 (C3) Levels at Week 48 of Part A and Week 168 of Part B | Part A: IgAN Subjects | 153.17 | 95% Confidence Interval 27.94 to 278.39 | milligram per deciliter | |
| Parts A and B: Change From Baseline in Serum Complement 3 (C3) Levels at Week 48 of Part A and Week 168 of Part B | Part A: PMN Subjects | 324.00 | 95% Confidence Interval NA to NA | milligram per deciliter | |
| Parts A and B: Change From Baseline in Serum Complement 3 (C3) Levels at Week 48 of Part A and Week 168 of Part B | Part A: C3G Subjects | 194.43 | 95% Confidence Interval 109.45 to 279.41 | milligram per deciliter | |
| Parts A and B: Change From Baseline in Serum Complement 3 (C3) Levels at Week 48 of Part A and Week 168 of Part B | Part B: IgAN Subjects | -74.00 | 95% Confidence Interval -506.01 to 358.01 | milligram per deciliter | |
| Parts A and B: Change From Baseline in Serum Complement 3 (C3) Levels at Week 48 of Part A and Week 168 of Part B | Part B: C3G Subjects | -48.50 | 95% Confidence Interval -214.73 to 117.73 | milligram per deciliter | |
| Parts A and B: Change From Baseline in Alternative Pathway Hemolytic Assay (AH50) Activity at Week 48 of Part A and Week 168 of Part B | Part A: IgAN Subjects | -17.3 | 95% Confidence Interval -71.0 to 36.3 | units per milliliter | |
| Parts A and B: Change From Baseline in Alternative Pathway Hemolytic Assay (AH50) Activity at Week 48 of Part A and Week 168 of Part B | Part A: PMN Subjects | -48.0 | 95% Confidence Interval NA to NA | units per milliliter | |
| Parts A and B: Change From Baseline in Alternative Pathway Hemolytic Assay (AH50) Activity at Week 48 of Part A and Week 168 of Part B | Part A: C3G Subjects | 4.0 | 95% Confidence Interval -59.7 to 67.7 | units per milliliter | |
| Parts A and B: Change From Baseline in Alternative Pathway Hemolytic Assay (AH50) Activity at Week 48 of Part A and Week 168 of Part B | Part B: IgAN Subjects | 9.0 | 95% Confidence Interval -16.4 to 34.4 | units per milliliter | |
| Parts A and B: Change From Baseline in Alternative Pathway Hemolytic Assay (AH50) Activity at Week 48 of Part A and Week 168 of Part B | Part B: C3G Subjects | 27.0 | 95% Confidence Interval -89.7 to 143.7 | units per milliliter | |
| Parts A and B: Change From Baseline in C3a Concentrations at Week 48 of Part A and Week 168 of Part B | Part A: IgAN Subjects | 1283.93 | 95% Confidence Interval -1963.09 to 4530.95 | microgram per liter | |
| Parts A and B: Change From Baseline in C3a Concentrations at Week 48 of Part A and Week 168 of Part B | Part A: PMN Subjects | 56.30 | 95% Confidence Interval NA to NA | microgram per liter | |
| Parts A and B: Change From Baseline in C3a Concentrations at Week 48 of Part A and Week 168 of Part B | Part A: C3G Subjects | 55.16 | 95% Confidence Interval -173.33 to 283.65 | microgram per liter | |
| Parts A and B: Change From Baseline in C3a Concentrations at Week 48 of Part A and Week 168 of Part B | Part B: IgAN Subjects | -10.00 | 95% Confidence Interval -41.77 to 21.77 | microgram per liter | |
| Parts A and B: Change From Baseline in C3a Concentrations at Week 48 of Part A and Week 168 of Part B | Part B: C3G Subjects | -100.65 | 95% Confidence Interval -361.20 to 159.90 | microgram per liter | |
| Parts A and B: Change From Baseline in Serum Albumin Levels at Week 48 of Part A and Week 168 of Part B | Part A: IgAN Subjects | -0.17 | 95% Confidence Interval -0.81 to 0.48 | gram per deciliter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03453619/results